NanoMab Technology Limited is a privately held biopharmaceutical company in the development of next generation cancer precision medicine. We are developing medicine for fast and specific delivery of radiation to treat cancer. A therapeutic product is made by a camelid antibody labelled with a radioisotope of therapeutic radiation. This therapeutic product is paired with a diagnosis, using the same antibody vector but labelled with a lower radiation radioisotope for imaging. Our goal is to develop a pipeline of therapeutic and diagnostic pairs, using our proprietary platform of camelid antibodies and of labelling radioisotopes onto the antibodies.
| Website | http://www.nano-mab.com |
| Revenue | $6 million |
| Employees | 6 (2 on RocketReach) |
| Founded | 2016 |
| Phone | +86 21 6229 9192 |
| Industry | Pharmaceutical Manufacturing, Manufacturing General, Manufacturing |
| Keywords | Cancer Therapeutics, Cancer Treatment, Precision Medicine, Radiotherapy, Next Generation Medicine, Antibody Drug Conjugates, Targeted Drug Delivery, Innovative Cancer Therapies, Radiation Therapy, Nanomedicine, Immunotherapy, Oncology, Cancer Research, Targeted Therapies, Drug Development, Cancer Diagnostics, Clinical Trials, Pharmaceutical Research, Molecular Medicine |
| Competitors | Roche, Thermo Fisher Scientific, Bio-Techne, abcam, GenScript, Miltenyi Biotec, R&D Systems, Cell Signaling Technology (CST), Mabtech, SAB Biotherapeutics , Inc. +44 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies |
Looking for a particular NanoMab employee's phone or email?
NanoMab Questions
The NanoMab annual revenue was $6 million in 2026.
Gitasha C is the Managing Director of NanoMab.
2 people are employed at NanoMab.
The NAICS codes for NanoMab are [325, 3254, 32, 32541].
The SIC codes for NanoMab are [28, 283].
Top NanoMab Employees
Related Companies
